Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07469566

Characterization of the Natural History of Microduplication Syndrome 7q11.23

7q11.23 duplication syndrome (7q duplication syndrome/7DUP) is caused by a microduplication of the 7q11.23 chromosomal region, encompassing 26-28 genes, including the GTF2I gene. This syndrome, often considered as a "mirror" phenotype of Williams-Beuren syndrome (WBS), is characterized by a wide range of neurodevelopmental impairments, including a neurodevelopmental disorder (NDD), autism spectrum disorders (ASD), selective mutism, mild dysmorphic features, and aortic dilation. Notably, one of the core clinical features of 7DUP is socialization impairment, which varies in severity across individuals.

The GTF2I gene, identified as critical in the pathogenesis of both WBS and 7DUP, exhibits opposite expression patterns in the two syndromes, with reduced expression in WBS and overexpression in 7DUP. The gene's dysregulation in 7DUP plays a pivotal role in the pathogenesis of the associated NDD and social deficits. Despite progress in characterizing the genetic underpinnings of 7DUP, there remains a critical gap in understanding the developmental trajectory of socialization impairments in affected individuals, especially during their transition through different developmental stages, from early childhood to adulthood.

Recent advancements in the study of neuronal models derived from induced pluripotent stem cells (iPSCs) and brain organoids have shed light on the molecular mechanisms driving 7DUP-related NDDs. Histone deacetylase inhibitors (HDAC inhibitors), which have been widely used in oncology, have shown promising preliminary results in reducing abnormal GTF2I expression in glutamatergic neurons differentiated from 7DUP patient-derived iPSCs. Preclinical studies in mouse models further demonstrated that these drugs can ameliorate socialization deficits, highlighting their therapeutic potential in addressing the core neurodevelopmental challenges in 7DUP.

However, despite these advancements, no longitudinal clinical studies have characterized the developmental trajectory of socialization impairments in 7DUP patients. Understanding this trajectory is critical, as it can inform the timing and potential impact of therapeutic interventions, such as HDAC inhibitors. Given the complexity and variability of the 7DUP phenotype, a comprehensive clinical characterization of socialization impairments across the lifespan is essential to improve diagnostic accuracy, optimize intervention strategies, and ultimately improve patient outcomes.

The aim of this research is to characterize the developmental trajectory of socialization impairments in patients with 7DUP, from early childhood through adulthood. By identifying patterns of socialization difficulties, this innovative study will allow to efficiently prepare future therapeutic trials, by specifying the phenotype of the patients, and by determining the most relevant outcome measures, taking into account, on one hand, their neurodevelopmental involvement and, on the other hand, the type of experimental design to be used in the context of rare diseases.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

7q11.23 Microduplication Syndrome (7DUP) Autism Spectrum Disorder Autism Spectrum Disorder (ASD) Child Development Disorders, Pervasive Mental Disorders Neurodevelopmental Disorders Neurodevelopmental Disorders (NDD) Williams-Beuren Region Duplication Syndrome

Age range

5 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Developmental Anomalies Reference Center, Genetics Department Woman Mother and Child Hospital, University Hospital of Lyon, Hospices Civils de Lyon, Bron, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of 7q11.23 microduplication confirmed by Chromosomal Microarray Analysis or qPCR.
  • Aged > 5 to < 50 years
  • Whose maternal language is French
  • Having signed the informed consent and/or for whom parents/legal guardian have signed the informed consent.
  • Affiliated to national Health Insurance system (sécurité sociale) or parents/legal guardian affiliated to national health insurance system Each 7DUP patient will be matched to a sex- and chronological age-matched control. Data from controls will come from the CREAT_criteria study (NCT 06018519). Each 7DUP patient will be matched to a sex- and mental age-matched control. Data from controls will come from the CREAT_criteria study (NCT 06018519).

Exclusion criteria

  • Refusal of the subject and/or the subject's parents/legal guardian to sign the informed consent
  • Refusal of the subject and/or the subject's parents/legal guardian to be informed of possible abnormalities detected during the neuropsychological assessment.

Regarding specifically the neuroimaging data (MRI):

  • Having a contraindication to the MRI examination (people using a pacemaker or an insulin pump, people wearing a metal prosthesis or an intracerebral clip, and claustrophobic subjects).
  • Refusal of the subject and/or the subject's parents/legal guardian to be informed of possible abnormalities detected by MRI.

Treatment and study plan

Clinical Assessment

Other

Clinical examination including Medical history, developmental trajectory, epilepsy history, clinical examination, actimetry over 24hours, podometry, 6 minutes walk test at the inclusion visit by a neuropediatrist.

Parental questionnaires

Other

Parental questionnaires including Vineland Adaptive Behavior scale second edition (Vineland II) , SRS-2, CBI, Beach Center Family Quality Of Life , PPD-MRS, Dunn sensory profile, ABC, Nisonger Child Behavior Rating, PEDSQL, Pediatric Quality of Life Inventory , San Martin Scale completed at the inclusion visit.

Cognitive Assessment

Other

Cognitive assessment including Leiter-3, Bayley-4 (if Leiter-3 not possible), CPM-BF, 4 sub-tests from the WPPSI-IV, 4 sub-tests from KITAP.PPVT 5, EVT 3, EXALANG 3-6 and automatic language analysis will be performed at the inclusion visit.

Reasoning assessment

Device

Simple reasoning tasks on tablets performed at the inclusion visit.

Motor assessment

Other

Purdue-Pegboard test , Kinematic task and Renzi scale will be performed at inclusion visit.

Social assessment

Other

Two eye-tracking tasks, ADOS, theory of mind assessment will be performed at inclusion visit.

Brain MRI (structural and functional)

Other

Optional brain MRI acquisition (structural and functional) will be performed at inclusion visit.

Primary outcomes

  1. Developmental trajectory tracking through age of acquisition in months.

    Time frame: At inclusion visit

    • Age at head control acquisition in months,

  2. Developmental trajectory tracking

    Time frame: At inclusion visit

    • Age at sitting alone in months,

  3. Developmental trajectory tracking

    Time frame: At inclusion visit

    • Age at walking alone in months,

  4. Developmental trajectory tracking

    Time frame: At inclusion visit

    • Age at running in months,

  5. Developmental trajectory tracking

    Time frame: At inclusion visit

    • Age at climbing stairs alternately in months,

  6. Adaptive assessment of skills (communication, daily life, socialisation, and motor skills)

    Time frame: At inclusion visit

    • based on interview with the parents of the patient
    • and with the VABS2 (Vineland Adaptive Behaviour Scale second edition)

  7. Description of the global social assessment from the ADOS scale score [0-28]

    Time frame: At inclusion visit

    • Social assessment: score [0-28] from the ADOS scale (Autism Spectrum Disorder)
    • A score >7 indicated characteristics of autism spectrum disorder.

  8. Description of the global autism spectrum disorder (ASD)

    Time frame: At inclusion visit

    • through parental questionnaires
    • score (range 0-19) derived from the Pervasive Developmental Disorder in Mentally Retarded Persons Scale (PDD-MRS).
    • A score > 10 is positive for an autism spectrum disorder.

Secondary outcomes

  1. Full-Scale Intelligence Quotient (FSIQ)

    Time frame: At inclusion visit

    The Full-Scale Intelligence Quotient (FSIQ) is a standardized measure of global cognitive functioning, with scores ranging from 40 to 160. It is assessed using age-appropriate Wechsler scales: Wechsler Preschool and Primary Scale of Intelligence Fourth Edition (WPPSI-IV) for children aged 5-6 years, Wechsler Intelligence Scale for Children Fifth Edition (WISC-V) for children older than 6 years, and Wechsler Adult Intelligence Scale Fourth Edition (WAIS-IV) for individuals older than 16 years. An IQ score below 70 is indicative of intellectual disability.

  2. Nonverbal Intelligence Quotient (NVIQ)

    Time frame: At inclusion visit

    The Nonverbal Intelligence Quotient (NVIQ) is a standardized measure of nonverbal cognitive functioning, with scores ranging from 30 to 170. It is assessed using the Leiter International Performance Scale Third Edition (Leiter-3) when Wechsler scales cannot be administered. The assessment includes four cognitive subtests to derive the nonverbal IQ score and two additional subtests evaluating nonverbal memory. An IQ score below 70 is indicative of intellectual disability.

  3. Epilepsy Status

    Time frame: At inclusion visit

    Epilepsy status is recorded as a dichotomous variable (Yes/No) based on information extracted from the participant's medical file at the inclusion visit. This outcome reflects the presence or absence of a documented diagnosis of epilepsy at the time of study enrollment.

  4. Atypical Sensory Profile Type

    Time frame: At inclusion visit

    The type of atypical sensory profile (auditory, visual, tactile, and movement-related) is determined using the Dunn Sensory Profile. This assessment is based on parent-completed questionnaires evaluating patterns of hypo- and hypersensitivity across the specified sensory domains.

  5. 24-Hour Activity and Sleep Duration (Minutes)

    Time frame: At inclusion visit

    Total duration of physical activity (minutes) and total sleep duration (minutes) over a 24-hour period, measured using actimetry data collected at the inclusion visit. This outcome is derived from objective actigraphy recordings quantifying movement-based activity and sleep patterns across a continuous 24-hour monitoring period.

Study contacts

Contact information is provided by the study sponsor or research team.

Dr Massimiliano ROSSI

CONTACT

[email protected]

+33 (0)4.27.85.55.72

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Official study title

Characterization of the Natural History of Microduplication Syndrome

Acronym: HINADU7

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Mar 13, 2026
Registry last updated
Mar 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.